Cambridge Enterprise et al. invest in DefiniGen

Cambridge-based DefiniGen has raised a total of £2.28m for its series-A funding round, with the latest £1m investment bringing it to a final close.

Existing investors include the CEO of Abcam – a producer of protein research tools – Providence Investment Company and Cambridge Capital Group. New investors include London Business Angels, Wren Capital and Ranworth Capital.

The capital injection will see the company expand its direct commercial presence across Europe, North America and Asia Pacific with a dedicated local marketing presence, invest in automation at its enlarged laboratory facility and aim to recruit more production staff. DefiniGen is also looking to expand its offerings in new areas and to strengthen its intellectual property portfolio.

Company
Founded in April 2012 to industrialise the OptiDiff stem cell production platform developed at the University of Cambridge, DefiniGen produces high-functionality cell types to support the development of safer and more effective treatments for disease. The technology platform also utilises humanised conditions required for the development of regenerative medicine and cellular therapies.

DefiniGen generated its first sales within six months of receiving seed investment and secured contracts with global pharmaceutical companies.

People
Marcus Yeo is the CEO of DefiniGen.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• UK / Ireland
• Expansion
• Healthcare
• United Kingdom